SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Acadia Pharmaceuticals Inc. – ‘S-8’ on 8/8/22

On:  Monday, 8/8/22, at 6:58pm ET   ·   As of:  8/9/22   ·   Effective:  8/9/22   ·   Accession #:  1193125-22-215187   ·   File #:  333-266680

Previous ‘S-8’:  ‘S-8’ on 8/6/20   ·   Next & Latest:  ‘S-8’ on 2/7/23   ·   12 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/09/22  Acadia Pharmaceuticals Inc.       S-8         8/09/22    5:190K                                   Donnelley … Solutions/FA

Registration Statement – Securities for an Employee Benefit Plan   —   Form S-8   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     35K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML      9K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 5: EX-FILING FEES  Filing Fees                                     HTML     15K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML    128K 


‘S-8’   —   Registration Statement – Securities for an Employee Benefit Plan

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Power of Attorney (included on the signature page)

This is an HTML Document rendered as filed.  [ Alternative Formats ]



  S-8  

As filed with the Securities and Exchange Commission on August 8, 2022

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

ACADIA PHARMACEUTICALS INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   06-1376651

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

12830 El Camino Real, Suite 400

San Diego, CA 92130

(858) 558-2871

(Address of Principal Executive Offices, Including Zip Code)

Acadia Pharmaceuticals Inc.

2010 Equity Incentive Plan

(Full Title of the Plan)

Austin D. Kim

Executive Vice President, General Counsel & Secretary

Acadia Pharmaceuticals Inc.

12830 El Camino Real, Suite 400

San Diego, CA 92130

(Name and Address of Agent for Service)

(858) 558-2871

(Telephone Number, Including Area Code, of Agent for Service)

 

 

Copies to:

L. Kay Chandler, Esq.

Carlos Ramirez, Esq.

Cooley LLP

4401 Eastgate Mall

San Diego, CA 92121

(858) 550-6000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


INCORPORATION BY REFERENCE OF CONTENTS OF

REGISTRATION STATEMENTS ON FORM S-8

The contents of: (i) the Registration Statement on Form S-8 (File No. 333-168667) originally filed with the Securities and Exchange Commission on August 9, 2010, as subsequently amended on August 19, 2011; (ii) the Registration Statement on Form S-8 (File No. 333-190400) filed with the Securities and Exchange Commission on August 6, 2013; (iii) the Registration Statement on Form S-8 (File No.  333-207971) filed with the Securities and Exchange Commission on November 12, 2015; (iv) the Registration Statement on Form S-8 (File No.  333-213109) filed with the Securities and Exchange Commission on August 12, 2016; (v) the Registration Statement on Form S-8 (File No.  333-219785) filed with the Securities and Exchange Commission on August 8, 2017; (vi) the Registration Statement on Form S-8 (File No.  333-226834) filed with the Securities and Exchange Commission on August 14, 2018; and (vii) the Registration Statement on Form S-8 (File No.  333-232981) filed with the Securities and Exchange Commission on August 2, 2019 are each incorporated by reference herein.

Item 8. Exhibits

 

Exhibit

Number

  

Description

  4.1    Amended and Restated Certificate of Incorporation, as Amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed August 6, 2015).
  4.2    Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K, filed February 25, 2021).
  4.3    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed September 12, 2013).
  4.4    Form of common stock certificate of the Registrant (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-52492, filed December 21, 2000).
  5.1*    Opinion of Cooley LLP.
23.1*    Consent of Independent Registered Public Accounting Firm.
23.2*    Consent of Cooley LLP (included in Exhibit 5.1).
24.1*    Power of Attorney (included on the signature page).
99.1*    2010 Equity Incentive Plan, as amended.
107*    Filing Fee Table.

 

* 

Filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 8, 2022.

 

ACADIA PHARMACEUTICALS INC.
By:  

/s/ Stephen R. Davis

  Stephen R. Davis
  Chief Executive Officer


POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen R. Davis and Austin D. Kim, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

       

Title

       

Date

/s/ Stephen R. Davis

Stephen R. Davis

     

Chief Executive Officer and Director

(Principal Executive Officer)

      August 8, 2022

/s/ Mark C. Schneyer

Mark C. Schneyer

     

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

      August 8, 2022

/s/ James K. Kihara

James K. Kihara

      Vice President, Chief Accounting Officer and Controller
(Principal Accounting Officer)
      August 8, 2022

/s/ Stephen R. Biggar

Stephen R. Biggar

      Chairman of the Board       August 8, 2022

/s/ Julian C. Baker

Julian C. Baker

      Director       August 8, 2022

/s/ Laura A. Brege

Laura A. Brege

      Director       August 8, 2022

/s/ James M. Daly

James M. Daly

      Director       August 8, 2022

/s/ Elizabeth A. Garofalo

Elizabeth A. Garofalo

      Director       August 8, 2022

/s/ Edmund P. Harrigan

Edmund P. Harrigan

      Director       August 8, 2022

/s/ Daniel B. Soland

Daniel B. Soland

      Director       August 8, 2022

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing    Date    Other Filings
Filed as of / Effective on:8/9/2210-Q
Filed on:8/8/2210-Q,  8-K
 List all Filings 


12 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/25/21  Acadia Pharmaceuticals Inc.       10-K       12/31/20   80:13M                                    ActiveDisclosure/FA
 8/02/19  Acadia Pharmaceuticals Inc.       S-8         8/02/19    3:54K                                    Donnelley … Solutions/FA
 8/14/18  Acadia Pharmaceuticals Inc.       S-8         8/14/18    3:51K                                    Donnelley … Solutions/FA
 8/08/17  Acadia Pharmaceuticals Inc.       S-8         8/08/17    3:52K                                    Donnelley … Solutions/FA
 8/12/16  Acadia Pharmaceuticals Inc.       S-8         8/12/16    3:49K                                    Donnelley … Solutions/FA
11/12/15  Acadia Pharmaceuticals Inc.       S-8        11/12/15    5:85K                                    Donnelley … Solutions/FA
 8/06/15  Acadia Pharmaceuticals Inc.       10-Q        6/30/15   43:1.7M                                   Donnelley … Solutions/FA
 9/12/13  Acadia Pharmaceuticals Inc.       8-K:5       9/06/13    2:179K                                   SEC Connect
 8/06/13  Acadia Pharmaceuticals Inc.       S-8         8/06/13    3:65K                                    Donnelley … Solutions/FA
 8/19/11  Acadia Pharmaceuticals Inc.       S-8 POS     8/19/11    1:34K                                    Donnelley … Solutions/FA
 8/09/10  Acadia Pharmaceuticals Inc.       S-8         8/09/10    3:62K                                    Donnelley … Solutions/FA
12/21/00  Acadia Pharmaceuticals Inc.       S-1                   28:1.7M                                   Toppan Merrill-FA2/FA
Top
Filing Submission 0001193125-22-215187   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 25, 9:33:23.2pm ET